The mycosis fungoides market is set to project sublime growth at a compounded annual growth rate (CAGR) of 4.9% during the forecast period from 2019 to 2027. Mycosis fungoides occur in 70% of the patients suffering from cutaneous T-cell lymphoma (CTCL), initially affecting the skin; later, the infection spreads to internal organs in the later stages of the disease.
Currently, combinatorial treatment regimens are employed by oncologists worldwide to subdue the clinical manifestations occurring during the course of the disease. SGX301 (Soligenix, Inc.) and 0.5% naloxone hydrochloride lotion (Elorac, Inc.) are currently in phase III clinical trials being studied for their safety and efficacy in the treatment of mycosis fungoides.
Market Synopsis
Recent USFDA approval of Poteligeo for the treatment of mycosis fungoides will increase the demand for monoclonal antibodies as a treatment regime.
As per the new guidelines formulated by the National Comprehensive Cancer Network (NCCN), there is no permanent cure for mycosis fungoides. The treatment regimen comprises individual and combinatorial therapy, depending on the stage and severity of the disease. Usually, topical steroids and mechlorethamine gel are used as a topical treatment in the early stage of the disease; if need be, localized radiation therapy is also recommended by oncologists depending upon the spread of mycosis fungoides.
HDAC inhibitors and extracorporeal photopheresis are prescribed to patients in stage 2 of the disease. During the late stages of mycosis fungoides, monoclonal antibodies are administered via systemic circulation. The recent approval by the USFDA for Poteligeo (mogamulizumab) will further boost the demand for monoclonal antibodies as the first line of treatment for mycosis fungoides during the forecast period.
In North America, market growth is being driven by the rising incidence of mycosis fungoides and stringent treatment guidelines mandated by the USFDA.
North America is presently ruling the regional segment for the mycosis fungoides market, representing a share of 31.8%. The parameters responsible for its impressive market growth are the rising incidence of mycosis fungoides and the stringent treatment guidelines stipulated by the US. According to the National Institute of Health (NIH), the prevalence of mycosis fungoides in the United States ranges from 3 to 6 per 100,000 people per year.
The presence of major players such as Sanofi S.A., Astellas Pharma, Soligenix, Inc., Yaupon Therapeutics, etc., further bolsters market growth in the North American region. Europe is in second place, holding a market share of 28.4%, primarily due to favourable reimbursement scenarios pertaining to the treatment of mycosis fungoides in the E.U. region.
Strategic collaboration between biopharmaceutical companies and academic research institutes further strengthens the market's growth in the European region. Asia Pacific, with a market share of 16.2%, is keen to register rapid growth on account of the supportive regulatory environment provided by the local healthcare agencies and proactive government policies to treat orphan and rare diseases.
Periods of History and Forecast
This research report presents the analysis of each segment from 2017 to 2027, considering 2018 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2019 to 2027.
Report Scope by Segments
The market is segmented by treatment and by geography.
Biopharmaceutical giants spearheading the mycosis fungoides market are Astellas Pharma, Bayer AG, Dover Medical and Scientific Equipment, Ltd., Elorac, Inc., Kyowa Kirin, Inc., Macopharma, Sanofi SA, Soligenix, Inc., Varian Medical Systems, and Yaupon Therapeutics.
Key questions are answered in this report.
Who are the major biopharmaceutical companies actively engaged in the development of medicines for the treatment of mycosis fungoides?
What are the DROs related to the market growth assessed as per the latest market trend?
What is the disease pathology pertaining to Mycosis fungoides, and what are its different stages?
What are the individual and combinatorial therapy employed for the treatment of mycosis fungoides?
What is the prevalence rate of Mycosis fungoides in developing regions such as Asia Pacific, MEA, and LATAM?
Frequently Asked Question:
The market for Mycosis Fungoides Market is expected to reach USD$ XX in 2027.
The Mycosis Fungoides Market is expected to see significant CAGR growth over the coming years, at 4.9%.
The report is forecasted from 2019 -2027.
The base year of this report is 2018.
Bayer AG, Dover Medical and Scientific Equipment, Ltd., Elorac, Inc., Kyowa Kirin, Inc., Macopharma, Sanofi SA. are some of the major players in the global market.
